NIH Research Festival
Introduction: Current gold standard treatment for early stage breast cancer is surgery with radiation and systemic treatment as needed. However, compared to surgery, less invasive approaches, such as ablative therapies, may have advantages including reduced scarring and pain potentially making these alternatives attractive for some patients. This review aims to further understand the usefulness of ablative therapies in DCIS/early stage breast cancer, by examining existing literature on laser, cryoablation, microwave, ultrasound (US) and radiofrequency ablation (RFA). Methods: Articles were selected according to PRISMA guidelines, and reviewed in three phases: 1) titles 2) abstracts and 3) full articles. Two independent reviews were performed to confirm relevance and abstract data. Discrepancies were discussed with a third independent reviewer. Results: The initial PubMed search yielded 1251 articles, and 75 relevant articles were identified; laser (n=9), cryoablation (n=12), microwave (n=4), RFA (n=29), US (n=19) and combination therapies (n=2). The results of laser, microwave and cryoablation therapy are presented. Breast cancer was diagnosed using core biopsy in 6/9 laser, 4/4 microwave and 7/12 cryoablation articles, of which DCIS was diagnosed in 18/253 patients (laser), 4/88 patients (microwave), 6/485 patients (cryoablation). Surgery was the most common follow-up technique. Complete ablation was observed in 72/253 patients (laser) and 39/88 patients (microwave). Discussion and Future Directions Ongoing review will examine the literature on US and RFA ablation. Our findings will compare and contrast ablative therapies in tumor destruction, and will further our understanding of the current knowledge of these therapies in treatment of early stage breast cancers.
Scientific Focus Area: Cancer Biology
This page was last updated on Friday, March 26, 2021